Avenge Bio

Avenge Bio was founded by an experienced team of proven biotech executives to develop transformative therapeutics which can potentially eradicate intractable solid tumors. Avenge Bio is developing our proprietary, allogeneic LOCOcyteTM platform for precision delivery of cytokines and other highly potent immunomodulatory molecules for a controlled period of time. Through this approach we are able to generate robust, local and systemic anti-tumor immune responses, without the toxicities associated with traditional immunotherapies. The LOCOcyteTM platform was developed from extensive research and experience of Dr. Omid Veiseh at Rice University and supported by Longitude Capital, CAM Capital, Perceptive Xontogeny, Rock Springs, Pappas Capital, and other leading healthcare investors. Together we are using the strength and efficiency of our platform to create a broad pipeline of therapeutics that target a wide range of difficult to treat solid tumors.

Webinar on Clinical Manufacturing

Zeke Johnston - Senior Director, External Manufacturing & Supply Chain at Avenge Bio

Michael Heffernan on LinkedIn: I am excited to announce the closing of Avenge Bio's $45 million Series A…

Douglas Carlson email address & phone number Avenge Bio Chief Operating and Financial Officer contact information - RocketReach

Biotech, Pharmaceutical and Clinical Research News

Enrollment information for DRUG FACTORY Implants in Ovarian Cancer Trial is now up on the Clinical Trials website! 👏 Check here:, By Ovarcome

BioDome Group

Avenge Bio Developing Cell Generated Immunotherapies to Eradicate Solid Tumors

avengebio (@AvengeBio) / X

Rogue Trooper: Avenge the Quartz Zone Massacre (Games Workshop, 1987)